Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for predicting PD-L1 level in breast cancer tumor tissue by using peripheral blood PD-1/PD-L1

A PD-L1, breast cancer tumor technology, applied in measurement devices, biological tests, material inspection products, etc., can solve problems such as differences between the two groups of people

Active Publication Date: 2021-07-16
BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, there was no significant difference in the number of CD4+ T lymphocytes dually expressing PD-1 and CTLA-4 in peripheral blood mononuclear cells (PBMC) between normal breast and primary invasive breast cancer, but in There are differences between the two groups in TIL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting PD-L1 level in breast cancer tumor tissue by using peripheral blood PD-1/PD-L1
  • Method for predicting PD-L1 level in breast cancer tumor tissue by using peripheral blood PD-1/PD-L1
  • Method for predicting PD-L1 level in breast cancer tumor tissue by using peripheral blood PD-1/PD-L1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Basic Research Information

[0022] Study population:

[0023] A total of 83 cases of primary early-to-middle-stage breast cancer were selected in Beijing Shijitan Hospital from November 2018 to November 2019. They had not received any treatment, had no autoimmune diseases, ECOG > 2 points, and no heart, brain, kidney and other important organ functions. Incomplete. Peripheral blood was collected before treatment, and tissue samples were obtained by local excision or needle biopsy, and then standardized treatment was performed. All patients gave written informed consent, and the study was approved by the Hospital Ethics Committee. Immunohistochemical analysis:

[0024] Paraffin specimens of tumor tissue were obtained from patients. The Ki-67 index ≥ 14% is defined as high expression of Ki-67, and the molecular types of breast cancer cases are: Luminal A type (HER-2 negative, ER positive, low Ki-67 expression), Luminal B type (HER- 2 negative, ER positive,...

Embodiment 2

[0030] Embodiment 2 result and analysis

[0031] Expression of PD-1 / PD-L1 in blood and tissue samples:

[0032] Of the 83 cases that met the enrollment conditions, 77 cases were tested for the expression levels of PD-1 and PD-L1 on the surface of peripheral blood T lymphocytes, and 73 cases were subjected to tissue PD-1 and PD-L1 immunohistochemical staining. A total of 68 cases had matching tissue and peripheral blood PD-1 / PD-L1 levels. Of the 68 cases, 18 cases were Luminal A (26.5%), 33 cases were Luminal B (48.5%), and 11 cases were triple negative ( 16.2%), 6 cases (8.8%) of HER-2 overexpression.

[0033] The median percentage of PD-1 positive T lymphocytes in the blood was 15.2% (3.6%-41.2%); the median percentage of PD-L1 positive T lymphocytes was 0.7% (0.0%-6.5%) ( figure 1 A, 1B).

[0034] In the results of pathological immunohistochemistry, the expression of PD-L1 in peritumoral TILs had certain heterogeneity ( figure 2 A, 2B) 24 of 73 cases (32.9%) were proved t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of tumor diagnosis and treatment, and provides a method for predicting the PD-L1 level in breast cancer tumor tissue through peripheral blood PD-1 / PD-L1 and application of a corresponding reagent, and the method comprises a step of detecting the expression level of PD-1 and / or PD-L1 in circulating T lymphocytes, and a step of predicting the PD-L1 level in the tumor tissue on the basis of the expression level of PD-1 and / or PD-L1 in the circulating T lymphocytes. The research result shows that the clinical pathological state of a breast cancer patient may influence the PD-L1 positive T lymphocyte level in peripheral blood; the detection of PD-1 / PD-L1 positive lymphocytes in peripheral blood has the capability of evaluating the expression property of PD-L1 in breast cancer tissues, which indicates that the PD-1 / PD-L1 level on the surfaces of lymphocytes in a blood sample is expected to replace pathological tissues clinically to become an index of PD-L1 state evaluation.

Description

technical field [0001] This application belongs to the technical field of tumor diagnosis and treatment. Specifically, this application provides a method for predicting PD-L1 levels in breast cancer tumor tissue by peripheral blood PD-1 / PD-L1, which is characterized in that it includes detecting circulating T lymphocytes The expression level of PD-1 and / or PD-L1 in the tumor tissue, and the steps of predicting the level of PD-L1 in tumor tissue based on the expression level of PD-1 and / or PD-L1 in circulating T lymphocytes. Background technique [0002] In recent years, the incidence of breast cancer has been on the rise worldwide, and new treatment methods are constantly being explored. As a major breakthrough in immunotherapy, PD-1 and PD-L1 inhibitors were first approved for the treatment of non-small cell lung cancer and melanoma, which can improve the median progression-free survival and overall survival of patients, and are gradually being applied Other solid or hemat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/577G01N33/574
CPCG01N33/6872G01N33/6893G01N33/577G01N33/57415G01N33/57488G01N33/57496G01N2333/70521
Inventor 宋清坤李艳萍周全伍江平吕淑贞袁可玉
Owner BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com